Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
GSK Signs Three-Year Agreement with Protas to Streamline Clinical Trials
GSK Signs Three-Year Agreement with Protas to Streamline Clinical Trials
Read also
Preclinical Models Map Genetic Changes Behind Multiple Sclerosis Damage
University of Notre Dame researchers empirically compare CPZ and LPC preclinical models to study myelin loss and regeneration in multiple sclerosis.
FDA Approves First All-Oral Inqovi and Venclexta Regimen for AML Care
The FDA approved the all-oral combination of Inqovi and Venclexta for newly diagnosed acute myeloid leukemia in adults 75 or older or chemo-ineligible.
Regeneron Inks $2.3B Deal with Parabilis for Novel ADC-Like Therapies
Regeneron partners with Parabilis Medicines in a $2.3 billion deal to develop antibody-Helicon conjugates, a novel class of precision targeted therapies.
Harbour BioMed Preclinical Data Challenges Eli Lilly in Obesity Space
Harbour BioMed publishes preclinical data on LET003, an ACVR2A/2B antibody, showing promise as a rival to Eli Lilly's bimagrumab in obesity treatment.
